Optimizing broadly neutralizing antibodies via all-atom interaction modeling and pre-trained language models

Antibody optimization is a fundamental challenge, and the identification of antibody-antigen interactions is crucial in the optimization process. However, current methods cannot accurately predict antibody-antigen interactions, providing limited functional guidance to improve the time-consuming and costly traditional optimization techniques. Here, we present InterAb and InterAb-Opt, a unified computational framework that integrates all-atom modeling with antibody language models to predict antibody-antigen interactions and enable antibody optimization. Leveraging the proposed all-atom modeling approach, AtomInter, and pre-trained antibody language models, InterAb outperforms existing methods in predicting antibody specificity and antibody-antigen binding affinity. InterAb successfully identified influenza A virus-binding antibodies from an antibody library and accurately detected high-affinity antibodies in the AIntibody competition. Empowered by the robust functional insights from InterAb, InterAb-Opt was developed to optimize broadly neutralizing antibodies. For R1-32 antibody, biolayer interferometry results reveal that 85%, 80%, 90%, and 67.5% of the 40 InterAb-Opt-optimized antibodies exhibit enhanced binding affinities to wild-type SARS-CoV-2, Lambda, BQ.1.1, and EG.5.1, respectively, with a maximum improvement of up to 96-fold. For the newly emerging BA.2.86 and KP.3, 55% and 52.5% of the optimized antibodies notably transition from non-binding to binding. Neutralization assays demonstrated that the optimized antibodies exhibited enhanced neutralization activity across multiple targets, highlighting the capability of InterAb-Opt in engineering broadly neutralizing antibodies. This technology enables precise analysis of antibody-antigen interactions and optimization of broadly neutralizing antibodies, holding promise for addressing challenges in immune evasion and vaccine design.